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Growing evidence suggests that mood disorder is associated with insulin resistance and inﬂammation. Thus the eﬀects of
antidepressants on insulin sensitivity and proinﬂammatory responses will be a crucial issue for depression treatment. In this study,
we enrolled 43 non-diabetic young depressed males and adapted standard testing procedures to assess glucose metabolism during
4-week hospitalization. Before and after the 4-week antidepressant treatment, participants underwent oral glucose tolerance test
(OGTT) and frequently sampled intravenous glucose tolerance test (FSIGT). Insulin sensitivity (SI), glucose eﬀectiveness (SG),
acute insulin response, and disposition index (DI) were estimated using the minimal model method. The plasma levels of C-
reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and adiponectin were measured. The Hamilton
depression rating scale (HAM-D) total scores were reduced signiﬁcantly during the course of treatment. There were no signiﬁcant
changes in the parameters of SI,S G, and DI. Compared to drug na¨ ıve status, the level of plasma IL-6 was signiﬁcantly elevated
(0.77 to 1.30pg/ml; P = .001) after antidepressant therapy. However, the concentrations of CRP, TNF-α, and adiponectin showed
no diﬀerences during the course of treatment. The results suggest that antidepressants may promote stimulatory eﬀect on the IL-6
production in the early stage of antidepressant treatment.
1.Introduction
Depressive disorder is a complex and multifactorial disorder
with biological heterogeneity. Growing evidence suggests
the mood disorder is associated with insulin resistance
and inﬂammation [1, 2]. Findings also suggest an over-
lapping pathophysiology between depressive disorder and
insulin regulation. Some studies have demonstrated that
depressed individuals had higher glucose levels and insulin
resistance when they are symptomatic [3–6]. Epidemiologic
evidences showed that obesity correlated with depression,
and depressed adults have a 37% increased risk of devel-
oping type 2 diabetes [7–9]. Additionally, population-based
surveys have also evidenced that the prevalence rate of
d e p r e s s i o ni nd i a b e t e si sa r o u n d8 %t o2 5 %a n du pt o
40–80% for diabetic patients with physical complications
[10–12]. Comorbid depression in diabetic patients could
deter treatment adherence and increase the frequency of
medical complications. Therefore, identifying depression
and reversing negative mood have been cited as important
issues for diabetes care [13, 14].
Most antidepressant medications, including tricyclic
antidepressants (TCAs), selective serotonin reuptake
inhibitors (SSRIs), serotonin norepinephrine reuptake
inhibitors (SNRIs), and mirtazapine, increase levels of
monoaminergic serotonin and norepinephrine, and modify
the balance of the hypothalamus-pituitary-adrenal (HPA)
axis known to be associated with depression as well as
insulin resistance [15–17]. The cause-and-eﬀect relationship
between antidepressants and glucose metabolism is still2 Mediators of Inﬂammation
unclear [18]. The noradrenergic nortriptyline used to treat
depressive symptoms hinder glycemic control in diabetes
patients [19]. Compared to TCAs, SSRI antidepressants
were associated with an increased insulin sensitivity index
and reduced glycosylated hemoglobin (HbA1c) in depressed
patients [20–22]; however, a case study reported that
subjects treated with SSRIs became hyperglycemic [23].
Weight gain related to mirtazapine has not been well
established; however, Himmerich et al. reported that the
weight gain is not parallel to glucose intolerance through a
short treatment period [24]. Hence, the question of whether
antidepressants inﬂuence the insulin resistance still remains
unresolved.
Persistent depressed mood substantially increases the
risk of cardiovascular disease via regulating the cellular
immunoinﬂammatory responses. Formation of artheroscle-
rosis represents a series of metabolic changes and cel-
lular inﬂammatory responses [25]. Adipokines, such as
tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and
adiponectin secreted from adipocytes and immune cells are
predictors of vascular disease and insulin resistance [26].
Several studies have reported that lower plasma adiponectin
as well as higher levels of cytokines and C-reactive protein
(CRP),coexistintype2diabetesandarecontributoryfactors
for developing cardiovascular disease [27]. Some evidences
indicate that depressed mood could be accompanied by the
activationofcellularinﬂammation,andantidepressantshave
modulatory eﬀect on the production of cytokines, especially
activation of IL-6 secretion [28–30].
To date, there is no consensus on the relationship of
antidepressants and glucose-insulin homeostasis in the early
phase or long-term treatment regimens. In this study, the
eﬀectsofantidepressantsoninsulin-glucosehomeostasisand
alterations of proinﬂammatory cytokines would be veriﬁed
by a structured study procedure and homogenous depressed
subjects.
2.MaterialsandMethods
2.1. Subjects and Study Design. Participants were between
20 and 25 years of age with a body mass index (BMI) less
than 25kg/m2. All patient participants were recruited from
a single center to ensure patient homogeneity and uniform
procedural conduct. Depressed subjects, who were Han
Chinese and lived in Taiwan, were eligible for the study if
their fasting plasma glucose was less than 6.1mmol/L. No
patients had a history of systemic disease or family history
of diabetes. Persons using psychotropics or medications
known to alter glucose metabolism were excluded from
the study. Potential adverse events and study procedures
were explained to all participants, and informed consent
was obtained prior to study entry. This study was approved
by the Institutional Review Board in TriService General
Hospital for Human Studies.
Forty-three depressed males, who met the Diagnostic and
Statistical Manual of Mental Disorder, fourth edition (DSM-
IV) diagnostic criteria of major depressive disorder with
single episode, were recruited and interviewed by two psy-
chiatrists. All of the subjects were drug free at least one week
before participating in the study and were admitted to the
psychiatric ward due to symptom disturbance and potential
suicide risk. The severity of depression was evaluated with
the 21-item Hamilton depression rating scale (HAM-D).
Prior to drug randomization, the patients underwent an
oral glucose tolerance test (OGTT) and frequently sampled
intravenous glucose tolerance test (FSIGT) to ensure no
remarkable metabolic problems at baseline. The participants
were randomly assigned to one of four antidepressant treat-
ment groups in a 1:1:1:1 manner, maprotiline (n = 11),
ﬂuoxetine (n = 11), venlafaxine (n = 10), and mirtazapine
(n = 11), and titrated up to the optimal dosage range.
During hospitalization, a relatively uniform diet, was
served as isocaloric (30kcal/kg/day) meals derived from 15%
protein, 33% fat, and 52% carbohydrate sources. Meals were
contained 20%, 40%, and 40% of the daily total caloric
intake in each meal, respectively Daily activity, and exercises
were also provided. Except for study medications, other
psychotropic drugs (except lorazepam) were not permitted.
Alcohol and coﬀee were restricted during the study period.
Four weeks following antidepressant treatment and psychi-
atric intervention, participants underwent repeated mental
status evaluation, HAM-D rating, and OGTT and FSIGT
examinations.
2.2. Oral Glucose Tolerance Test (OGTT). After a 10-hour
overnight fast, OGTT was performed at 8:30 am by orally
administering a 75g glucose load in 150ml of free water.
Venous blood samples were obtained for plasma glucose and
insulin determination at 0, 30, 60, 90, 120, and 180 minutes
after glucose ingestion. The glucose and insulin areas under
curve in response to OGTT were determined. The indices
of basal insulin resistance and β-cell function were assessed
using the homeostasis model assessment (HOMA-IR and
HOMA-β) originally described by Matthews et al. in which
HOMA-IR (mmol/L × μIU/mL) = fasting glucose (mmol/L)
× fasting insulin (μIU/mL)/22.5 and HOMA-β = fasting
insulin (μIU/mL) × 20/[fasting glucose (mmol/L) − 3.5]
[31]. The insulinogenic index (measure of insulin secretion
during the OGTT) was calculated as the total incremental
plasma insulin divided by the total incremental plasma
glucose during the 2-hour OGTT period (insulin area under
the curve above the baseline/glucose area under the curve
above the baseline; represented as ΔI/ΔG) [32].
2.3. Frequently Sampled Intravenous Glucose Tolerance Test
(FSIGT). Aninsulin-modiﬁedFSIGTwith12bloodsamples
was performedto evaluate insulin sensitivity. An intravenous
50% glucose solution bolus (0.3g/kg) was injected smoothly
within 60 seconds at time 0 and a bolus (0.025U/kg)
of regular human insulin (Novo Nordisk Pharmaceutical,
Princeton, NJ, USA) was given 20 minutes later. Blood
samples were collected at 0, 2, 4, 8, 19, 22, 30, 40, 50, 70,
100, and 180 minutes.
Whole-body insulin sensitivity (SI) was calculated using
the Bergman minimal model [33]. Brieﬂy, SI is the increase
in the fractional clearance rate of glucose per unit change
in the plasma insulin concentration. Estimates of SI from
this model have been validated against the glucose clampMediators of Inﬂammation 3
technique. Acute insulin response (AIR) is the increment
in the plasma insulin concentration above baseline in the
ﬁrst 8 minutes after glucose administration and is used as
a sensitive measure of β-cell function. SG (glucose eﬀec-
tiveness, independent of insulin, on the glucose utilization
rate) is the glucose concentration at time 0 estimated by
extrapolating the prediction of the glucose kinetics model to
the moment of injection and obtained by using a minimal
model algorithm. The disposition index (DI) was deﬁned
as the product of AIR and SI that measures the ability
of pancreatic β-cell to compensate for insulin resistance
[34].
2.4. Laboratory Measurements. Following a 10-hour fast,
venous blood was obtained for determining plasma glucose,
insulin, thyroid hormone, cortisol, blood urea nitrogen
(BUN), creatinine, aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), and lipid proﬁles. Plasma
circulating adiponectin, CRP, TNF-α, and IL-6 levels were
also measured. Biochemistry and serum total cholesterol
were measured using a dry multilayer analytic slide method
in the Fuji Dri-Chem 3000 analyzer (Fuji Photo Film Cor-
poration, Minato-Ku, Tokyo, Japan). The determination of
serum triglyceride after enzymatic splitting with lipoprotein
lipase was assayed by colorimetric enzymatic test on Hitachi
717 (Biomedilines, San Diego, CA, USA), while the plasma
glucoseconcentrationwasdeterminedbytheglucoseoxidase
m e t h o do naB e c k m a nG l u c o s eA n a l y z e rI I( B e c k m a n
Instruments, Fullerton, CA, USA).
Plasma insulin was measured with a radioimmunoassay
kit (Coat-A-Count Insulin Kit, Diagnostic Products Cor-
poration, Los Angeles, CA, USA). The intra- and interas-
say coeﬃcients of variance (CV) were 3.3% and 2.5%,
respectively. Plasma CRP levels were measured using the
Tina-quant (Latex) high sensitive assay (Roche Diagnostics
GmbH,Mannheim,Germany).Cortisolassaywasacompeti-
tiveimmunoassayusingdirectchemiluminescenttechnology
(Bayer HealthCare LLC, Tarrytown, NY, USA). Thyroid
stimulating hormone (TSH) was determined using Coat-
A-Count TSH immunoradiometric assay (Los Angeles, CA,
USA), while triiodothyronine (T3) and nonprotein-bound
thyroxin (free T4) were assayed by the method of Coat-A-
Count T3 and free T4 solid-phase 125I radioimmunoassay
(Los Angeles, CA, USA).
Serum adiponectin concentrations were assayed with
radioimmunoassay established by Linco Research (St
Charles, MO, USA). Total adiponectin, in a range of high-
to low-molecular weight multimeric forms, were included.
This assay had a sensitivity of 1ng/mL and intra- and
interassay CV of less than 8%. Serum IL-6 concentrations
were determined by the method of human high sensitivity
Enzyme Linked-ImmunoSorbent Assay (ELISA) established
by Diaclone Research (Besancon Cedex, France). The intra-
and interassay CV for IL-6 were 1.4% and 5.5%, respectively.
Serum TNF-α was measured with the Biotrak high
sensitivity human ELISA kit from Amersham Biosciences
(Buckinghamshire, UK). The minimal detectable dose of
TNF-α was determined to be 0.1pg/mL, by adding two
standard deviations to the optical density value of zero
and calculating the corresponding concentration from the
standard curve. The intra- and interassay CV for TNF-α
were 5.8% and 9.3%, respectively.
2.5. Statistical Analyses. The sample size determination was
based on the power (β) in the response rate of depression.
To determine whether the distribution of each variable
approximatesnormaldistributionindepressedgrouptreated
with diﬀerent antidepressants, the Q-Q plot was adapted
to test normality. Statistical diﬀerences in the demographic
characteristics among the four groups of antidepressant
treatment were calculated by one-way analysis of variance
(ANOVA) with Tamhane’s post hoc test. To compare the
diﬀerences of glucose metabolic parameters, and adipokines
before and after antidepressant treatment, paired t test was
used. Statistical calculations were carried out using the SPSS
program for Windows (11.5.0 version, SPSS, Inc., Chicago,
IL,USA).Allvalueswereexpressedasmean ±standarderror
(SEM). P values less than .05 were considered statistically
signiﬁcant.
3. Results
The randomized treatment groups were similar for age, body
weight, BMI and HAM-D scores. The baseline parameters
of fasting glycemic index, liver, renal, thyroid functions and
morning cortisol level were all within normal limits and
similar between the treatment subgroups. Total cholesterol
(159.6 ± 7.3mg/dl) and total triglyceride (76.0 ± 5.4mg/dl)
were also within normal limits and similar between the
treatment subgroups.
At the baseline, the HAM-D total score was 31.1 and
decreased by 50% (P<. 005) following inpatient treatment.
Weight gain was found in maprotiline- and mirtazapine
treated groups (1.3 and 1.6kg, resp.). Although weight gain
was observed in 2 of the 4 treatment groups during the
course of intervention, the weight gain was not statistically
signiﬁcant and allowed the participants to be pooled for the
remainder of analyses.
There were no statistical changes in the fasting and
2 hour-plasma glucose, and insulin concentrations, based
on OGTT, after 4 weeks of antidepressant treatment.
Furthermore, the values for HOMA-IR, HOMA-β and
insulinogenic index remained unchanged following treat-
ment (Table 1); moreover, no diﬀerences were found
among the separated antidepressant subgroups by ANOVA
testing.
The plasma levels of glucose and insulin from the FSIGT
at baseline and posttreatment are presented in Figure 1.
There were no statistical changes in plasma glucose at
any time interval based on FSIGT between baseline and
posttreatment. Elevation in plasma insulin at 22-minutes
post glucose injection was signiﬁcantly higher posttreatment
than observed at baseline. To determine insulin sensitivity
and pancreatic B-cell function, we used Bergman’s minimal
model. No signiﬁcant changes in insulin sensitivity or B-cell
function were observed (Table 1), even analyzed in separated
antidepressantgroups.PlasmaIL-6wassigniﬁcantlyelevated
following the 4 week inpatient pharmaceutical intervention4 Mediators of Inﬂammation
Table 1: Diﬀerences of body weight, depressive symptoms, and metabolic parameters of glucose metabolism in depressed patients before
and after treatment.
Before After
(N = 43, mean ± SE) (N = 43, mean ± SE)
Age (years) 23.3 ± 0.4 22.3 ± 0.4
Body weight (kg) 65.7 ± 1.0 65.8 ± 1.1
BMI (kg/m2) 22.6 ± 0.3 22.1 ± 0.3
Systolic BP (mmHg) 119.6 ± 1.6 117.9 ± 1.4
Diastolic BP (mmHg) 76.8 ± 1.2 75.3 ± 0.9
HAM-D 31.1 ± 1.5 16.5 ± 1.7∗∗
HOMA-IR 1.11 ± 0.14 1.25 ± 0.15
HOMA-β 154.74 ± 56.20 273.09 ± 92.30
ΔI/ΔG( μIU/mg) 144.2 ± 13.8 149.9 ± 17.4
SI (10−5 min−1/pmol) 0.90 ± 0.09 0.70 ± 0.08
SG (min−1) 0.028 ± 0.003 0.035 ± 0.007
AIR (pmol) 3440 ± 424 4100 ± 419
DI (SI × AIR) 2871 ± 400 2968 ± 407
∗P<. 05
∗∗P<. 005.
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Figure 1: Blood concentrations of glucose (a) and insulin (b)
following frequently sampled intravenous glucose tolerance test
(FSIGT). The pre-treatment group (N = 43) is denoted as (◦), and
posttreatment group is denoted as (•). Vertical bars (for clarity only
the upper or lower portion is shown) represent standard error of
the means.
(Figure 2).However,CRP,TNF-α,andadiponectinremained
unchanged.
4. Discussion
This is the ﬁrst study demonstrating that short-term anti-
depressant treatment is associated with reduced depressive
symptoms and minimal anthropometric and metabolic
changes in a homogenous group of young Asian men. In
the study design, we recruited the nonobese subjects with
normal BMI (22.6 ± 0.3kg/m2) and the participants did
not show metabolic impairment at the baseline. In the
short-term antidepressant treatment, the overall response
rate was approximately up to 50%. There was weight gain
in the maprotiline and mirtazapine groups, but did not
show signiﬁcant diﬀerence. The ﬁnding of maprotiline and
mirtazapine-related weight gain is consistent with previous
literature reports; however, there was no raising body
weight by ﬂuoxetine and venlafaxine treatment in this study.
Comparingtopreviousliterature,theSSRIsorSNRIs-related
weight change is still inconclusive issues [15, 35].
Our ﬁndings showed no signiﬁcant diﬀerences in insulin
resistance or oﬀsetting beta-cell secretion deﬁned by OGTT
and FSIGT following antidepressant treatment. Regarding
the relationships between antidepressants and insulin sensi-
tivity, there are some discrepancies between our ﬁndings and
the previous studies [18, 21, 23, 36–39]. In preclinical animal
studies, Erenmenisoglu et al. investigated the metabolic dif-
ference between TCA and SSRI in mice and found that TCA
treatment induced hyperglycemia and hyperinsulinemia; in
contrast, the SSRI-treated group had reduced blood glucose
levels[40].ThisﬁndinghasbeenrefutedbyYamadaetal.and
Gomez et al. found that SSRIs could induce hyperglycemia
and increase plasma insulin levels in male rats and mice
models [39, 41]. From the clinical survey, TCA’s medications
couldinduceweightgainandhaveadverseeﬀectsinglycemicMediators of Inﬂammation 5
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Figure 2: Alterations in plasma concentrations of CRP, cytokines and adiponectin in depressed males following antidepressant treatment.
Open and gray bars represent as before and after antidepressant treatment, respectively.
control for diabetes patients [19]; however, SSRI antidepres-
s a n t sw e r ea b l et od e c r e a s et h ef a s t i n gg l u c o s el e v e la n d
reducelevelofglycosylatedhemoglobinindepressedpatients
[20–22]. To clarify these controversial issues, Okamura et al.
used FSIGT procedure and minimal model analysis and
demonstratedinsulinsensitivityindepressedpatientstreated
with tri/tetracyclic antidepressants showed improvement
through3-monthtreatment[35].ComparedtoHimmerich’s
results, it demonstrated that the glucose tolerance in the
OGTT was not correlated with mirtazapine-induced weight
gain [24]. Reviewing the literatures, we propose the plausible
discrepancy may be due to sampling variations such as body
weight, age, diet and concomitant psychotropic medications.
To control these sampling diversities in this study, we
recruited inpatient young depressed males, adjusted the diet
and conducted the structured procedures during the course
of treatment. Thus, this study would have the strength to
clarify the relationship between antidepressants and insulin
resistance.
Adiponectin is an adipocyte-derived hormone that is
inversely associated with insulin sensitivity and body weight.
In Figure 2, is resulted demonstrates without diﬀerence
of adiponectin level following antidepressant treatment, it
wouldbeprobablyattributedtoinsuﬃcientchangeofinsulin
sensitivity and weight gain in this study. Growing evidence
shows elevation of plasma IL-6 and TNF-α concentrations
in depressed and diabetic patients and IL-6 represents the
higher association with obesity and insulin resistance [42,
43]. TNF-α is an important stimulator of a second wave of
cytokines,includingIL-6andotherchemokines.Hinze-Selch6 Mediators of Inﬂammation
et al. demonstrated that the activation of TNF-α and weight
gain was induced by TCA and paroxetine antidepressants
during the course of treatment [44]. IL-6 is also secreted in
response to stress via enhancing noradrenergic neurotrans-
mission and stimulating the HPA axis which are regulated by
antidepressants [25]. Interestingly, our result demonstrated
the plasma IL-6 was signiﬁcantly elevated and independent
ofweightchange,adiponectinandTNF-αproductionduring
short-term antidepressant treatment; besides, not parallel to
thealterationofTNF-α.ThesigniﬁcantelevationofIL-6may
be attributed to the antidepressant modulatory eﬀects via
noradrenergic and/or serotonergic transmission on the adi-
posetissuesandimmunesystemsintheearlyantidepressant-
treated course. However, whether the increasing level of IL-6
is directly responsible antidepressants themselves is still an
undeﬁned issue. Furthermore, the balancing eﬀect between
the inﬂammatory IL-6 cytokine and anti-inﬂammatory
cytokines (e.g., IL-10) would need to clariﬁed in the future.
There were some limitations and weakness in this
study. First, it was lack of the corresponding controls,
such as untreated depressed group or nondepressed with
antidepressant-treated cohort. Second, the unequal and lim-
ited sample size in the diﬀerent subgroups of antidepressants
may restrict the statistical power and have potential chance
of type I error statistically. It is an intriguing issue to
explore the eﬀects of the diﬀerent antidepressants on glucose
metabolism, and the diﬀerent pharmacological mechanisms
and diverse neurotransmissions can inﬂuence the insulin
secretion and proinﬂammatory cytokine release.
In summary, our study provides a homogenous condi-
tion to clarify the glucose-insulin homeostasis in relation to
depression and antidepressant treatment. The results suggest
that antidepressants may lead to stimulatory eﬀect on the IL-
6 production in the early stage of antidepressant treatment;
however, the separated antidepressant and long-term eﬀects
still need to be clariﬁed by using larger samples.
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